Page last updated: 2024-11-05

1,3-dichloro-1-propene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

1,3-dichloro-1-propene: soil fumigant; RN given refers to cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1,3-dichloropropene : A chloropropene with two chloro substituents at positions 1 and 3 respectively.. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID24883
CHEMBL ID3561804
MeSH IDM0081651

Synonyms (15)

Synonym
542-75-6
1,3-dichloro-1-propene
1,3-dichloropropene
D0405
FT-0659222
FT-0659287
FT-0606653
1,3-dichioropropene
UOORRWUZONOOLO-UHFFFAOYSA-N
1,3 dichloropropene
AKOS025117018
CHEMBL3561804
cis-/trans-1,3-dichloropropene
trans-1,3-dichlorpropylene
1,3-dichloro-prop-1-ene

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" DCP is moderately toxic via oral or inhalation exposure, is irritating to the skin and eyes, and has potential to produce skin sensitization."( Mammalian toxicity of 1,3-dichloropropene.
Gollapudi, BB; Rao, KS; Stott, WT, 2001
)
0.31
" In an effort to develop safe practices for using TIF, a large field study was conducted in the San Joaquin Valley of California."( Emission and transport of 1,3-dichloropropene and chloropicrin in a large field tarped with VaporSafe TIF.
Ajwa, H; Gao, S; Qin, R; Stanghellini, M; Sullivan, D, 2013
)
0.39
" Because the airway epithelium varies along its length, with various regions composed of different cell types, we have introduced a known toxic vapor to five human-derived, differentiated, in vitro airway epithelial cell culture models-MucilAir of nasal, tracheal, or bronchial origin, SmallAir, and EpiAlveolar-representing five regions of the airway epithelium-nasal, tracheal, bronchial, bronchiolar, and alveolar."( NAM-based prediction of point-of-contact toxicity in the lung: A case example with 1,3-dichloropropene.
Andersen, ME; Barnwell, A; Corzine, S; Fisher, J; McMullen, PD; Moreau, M; Ranade, A; Slattery, SD, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The relatively high vapor pressure of 1,3-D, its short half-life in drinking water, and its reactivity with constituents of feed necessitated the use of a microencapsulated formulation (starch-sucrose shell) of 1,3-D in these studies."( Bioavailability and pharmacokinetics of microencapsulated 1,3-dichloropropene in rats.
Alexander, LM; Bartels, MJ; Brzak, KA; Dryzga, MD; Gilbert, JR; McGuirk, RJ; Mendrala, AL; Stott, WT, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The bioavailability of ingested microencapsulated 1,3-D was determined by characterizing and comparing the kinetics of 1,3-D in the blood of female F344 rats coadministered microencapsulated 1,3-D and neat 13C-1,3-D (25 mg/kg each) via gavage."( Bioavailability and pharmacokinetics of microencapsulated 1,3-dichloropropene in rats.
Alexander, LM; Bartels, MJ; Brzak, KA; Dryzga, MD; Gilbert, JR; McGuirk, RJ; Mendrala, AL; Stott, WT, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" Blood levels of 1,3-D and 13C-1,3-D displayed similar kinetics, peaking within 10 min of dosing followed by a rapid biphasic elimination."( Bioavailability and pharmacokinetics of microencapsulated 1,3-dichloropropene in rats.
Alexander, LM; Bartels, MJ; Brzak, KA; Dryzga, MD; Gilbert, JR; McGuirk, RJ; Mendrala, AL; Stott, WT, 1998
)
0.3
" In both the 13-week and the 1-year studies, the primary effect of 1,3-D in male and female dogs ingesting a dosage of >/=15 mg/kg/day was hypochromic, microcytic anemia."( Subchronic and chronic toxicity of ingested 1,3-dichloropropene in dogs.
Haut, KT; Quast, JF; Stebbins, KE; Stott, WT, 1999
)
0.3
" The first choice under the guidelines is to use a chemical-specific, biologically based dose-response (BBDR) model."( Applications of mechanistic data in risk assessment: the past, present, and future.
Dollarhide, JS; Dourson, ML; Haber, LT; Maier, A; Savage, RE; Zhao, Q, 2001
)
0.31
" Nonneoplastic changes from chronic dosing of DCP were generally similar to those observed in subchronic studies."( Mammalian toxicity of 1,3-dichloropropene.
Gollapudi, BB; Rao, KS; Stott, WT, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (184)

TimeframeStudies, This Drug (%)All Drugs %
pre-199032 (17.39)18.7374
1990's33 (17.93)18.2507
2000's67 (36.41)29.6817
2010's43 (23.37)24.3611
2020's9 (4.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.48%)5.53%
Reviews12 (5.71%)6.00%
Case Studies5 (2.38%)4.05%
Observational0 (0.00%)0.25%
Other192 (91.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]